News
Here's Why Spark Therapeutics, Inc. Fell 9.3% in October
Shares of Spark Therapeutics, Inc. (NASDAQ: ONCE), a clinical-stage biotech advancing a once-and-done gene therapy approach to treating genetic disorders, have given back some of August's gains.....
The Single Event That Rocketed Arena Pharmaceuticals, Inc. Higher by 10% in October
Shares of Arena Pharmaceuticals (NASDAQ: ARNA), a small-cap biotech company with a focus on a broad array of specialty disease indications, vaulted higher by 10% during the month of October,....
The Big Reason ImmunoGen, Inc. Shed 24% of Its Value in October
Shares of ImmunoGen (NASDAQ: IMGN), a small-cap biotech company focused on the development of antibody-drug conjugates for the treatment of cancer, plunged 24% in October, according to data from....
Here's Why Teligent Stock Was Cut Nearly in Half Today
Shares of specialty generic pharmaceutical manufacturer Teligent (NASDAQ: TLGT) dropped as much as 46% today after investors digested the company's third-quarter 2017 results. Operations appeared....
Why Celldex Therapeutics Jumped Higher Today
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is up 16% at 12:04 p.m. EST after releasing third-quarter earnings this morning, although the stock move likely has more to do with data released in....
Celldex Therapeutics, Inc.'s Most Important Takeaway From Q3 Isn't a Number
Investors view quarterly updates from clinical-stage biotechs in a very different way than they do for other companies. The bottom line isn't nearly as important for these small biotechs as are....
The Clear-Cut Reason Alexion Pharmaceuticals Tanked 15% in October
Shares of Alexion Pharmaceuticals (NASDAQ: ALXN), a large-cap biotech company with a focus on rare genetic diseases, tumbled 15% during the month of October, according to data from S&P Global....
The Clear-Cut Reason Alexion Pharmaceuticals Tanked 15% in October
Shares of Alexion Pharmaceuticals (NASDAQ: ALXN), a large-cap biotech company with a focus on rare genetic diseases, tumbled 15% during the month of October, according to data from S&P Global....
Here's Why Regeneron Pharmaceuticals Inc. Slipped 10% in October
Shares of Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) took a hit last month as investors adjusted their outlook for a recently launched eczema drug with megablockbuster potential. According to....
Here's Why Regeneron Pharmaceuticals Inc. Slipped 10% in October
Shares of Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) took a hit last month as investors adjusted their outlook for a recently launched eczema drug with megablockbuster potential. According to....
Here's Why Regeneron Pharmaceuticals Inc. Slipped 10% in October
Shares of Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) took a hit last month as investors adjusted their outlook for a recently launched eczema drug with megablockbuster potential. According to....
Why Celldex Therapeutics Stock Crumbled in October
Shares of the clinical-stage biotech Celldex Therapeutics (NASDAQ: CLDX) fell by 14.7% in October, according to S&P Global Market Intelligence. The good news -- if you can call it that -- is....
The Insurer That's Crushing It in Obamacare
Worry that Obamacare is on life support doesn't seem to scare Centene Corporation (NYSE: CNC) CEO Michael Neidorff. Over the past few years, he's been significantly increasing Centene's exposure....
Better Buy: Novavax, Inc. vs. Pfizer Inc.
Pfizer (NYSE: PFE) ranks as one of the giants of the pharmaceutical market, with a blockbuster vaccine franchise. Novavax (NASDAQ: NVAX) is only a fraction of Pfizer's size and is still at least a....
Better Buy: Novavax, Inc. vs. Pfizer Inc.
Pfizer (NYSE: PFE) ranks as one of the giants of the pharmaceutical market, with a blockbuster vaccine franchise. Novavax (NASDAQ: NVAX) is only a fraction of Pfizer's size and is still at least a....
Why AVEO Pharmaceuticals, Inc. Tanked 18.6% in October
Shares of AVEO Pharmaceuticals (NASDAQ: AVEO), a small-cap biopharma focused on cancer, fell 18.6% in October, according to data from S&P Global Market Intelligence. There doesn't appear to be....
The Only 3 Big Pharma Companies Growing Market Share
With worldwide spending on prescription drugs increasing from an estimated $774 billion in 2017 to over $1 trillion in 2022, a rising tide of pharmaceutical sales is lifting a lot of drug company....
Why Henry Schein, Inc. Is Falling
In response to the company's third-quarter earnings, shares of Henry Schein (NASDAQ: HSIC), a maker of medical products that are primarily used by dentists and veterinarians, fell as much as 10%....
Why Henry Schein, Inc. Is Falling
In response to the company's third-quarter earnings, shares of Henry Schein (NASDAQ: HSIC), a maker of medical products that are primarily used by dentists and veterinarians, fell as much as 10%....
Exelixis, Inc. Looks Ahead -- but the 3rd Quarter Wasn't Too Shabby
Exelixis (NASDAQ: EXEL), the biotech once left for dead by quite a few investors, continues its resurgence with another solid quarter of sales of its kidney cancer drug Cabometyx. Of course, the....
Keryx Biopharmaceuticals, Inc. Fell 8.6% In October -- Here's Why That Doesn't Matter
Shares of Keryx Biopharmaceuticals (NASDAQ: KERX), a commercial-stage biopharma focused on kidney disease, fell 8.6% in October according to data from S&P Global Market Intelligence. However,....
Here's Why Stemline Therapeutics Inc. Jumped 23% Higher in October
Shares of Stemline Therapeutics Inc. (NASDAQ: STML), a clinical-stage biotech developing therapies that target cancer stem cells, shot up 23% in October according to data from S&P Global....
BASTIDE : Déclaration du nombre d'actions et de droits de vote (31.10.2017)
BASTIDE LE CONFORT MEDICAL
Société Anonyme au capital de 3.303.261 euros
Siège social : 12 avenue de la Dame, Zone Euro 2000
30132 Caissargues
RCS de NIMES N° B 305 635 039
DROITS DE....
What's Behind GW Pharmaceuticals' 6.4% Gain in October?
Shares of GW Pharmaceuticals plc (NASDAQ: GWPH), a company developing an epilepsy drug derived from its cannabinoid product platform, tacked on another 6.4% in October according to data from....
GW Pharmaceuticals Just Delivered Some Good News About Its Marijuana-Based Drug
This year has been a real seesaw for shareholders of GW Pharmaceuticals (NASDAQ: GWPH). Lately, that seesaw is tipping up slightly, following news that a cannabidiol-based drug candidate the....